Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited

被引:14
|
作者
Spencer, K [1 ]
机构
[1] Harold Wood Hosp, Dept Clin Biochem, Endocrine Unit, Romford RM3 0BE, Essex, England
关键词
nuchal translucency; free beta-hCG; PAPP-A; trisomy; 21; counselling; prenatal screening;
D O I
10.1002/pd.430
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objectives To assess the level of correlation of first trimester biochemical and biophysical markers of Down syndrome between different pregnancies in the same individual. To assess the impact that between pregnancy biological variability has on the likelihood that women who are at increased risk in a first pregnancy being also at increased risk in a subsequent pregnancy. Methods During a three period women attending the OSCAR clinic at Harold Wood Hospital have had the opportunity to have first trimester screening for Down syndrome and other aneuploidies using the maternal serum biochemical markers free beta-human chorionic gonadotrophin (hCG) and pregnancy associated plasma protein-A (PAPP-A) in conjunction with fetal nuchal translucency (NT) thickness and maternal age. Of the 11 1105 women undergoing such screening, the computer records were examined for women who had more than one pregnancy. The results from 1002 women with two normal singleton pregnancies were available for analysis. Marker correlations (as MoM) were established between the pregnancies and the proportion of women likely to be at increased risk in each pregnancy estimated, as was the likelihood of women being at increased risk in both pregnancies. Results For fetal NT there was no correlation between NT MoM in the first and second pregnancy (r = 0.0959, p > 0.10). For maternal serum free beta-hCG MoM a significant correlation was found (r = 0.3976, p < 0.001), as was also found for PAPP-A MoM (r = 0.4371, p < 0.001). Conclusion The implication for such between pregnancy marker association is that women who have an increased risk of Down syndrome in one pregnancy are two or three times more likely to repeat this event in their next pregnancy. This information may be useful in counselling women when undergoing first trimester screening in a subsequent pregnancy. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:874 / 876
页数:3
相关论文
共 47 条
  • [31] In combined first-trimester Down syndrome screening, the false-positive rate is not higher in pregnancies conceived after assisted reproduction compared with spontaneous pregnancies
    Matilainen, Maarit
    Peuhkurinen, Sini
    Laitinen, Paivi
    Jarvela, Ilkka
    Morin-Papunen, Laure
    Ryynanen, Marku
    FERTILITY AND STERILITY, 2011, 95 (01) : 378 - 381
  • [32] Detection of trisomy 18 and trisomy 13 using first and second trimester Down's syndrome screening markers
    Bestwick, Jonathan P.
    Huttly, Wayne J.
    Wald, Nicholas J.
    JOURNAL OF MEDICAL SCREENING, 2013, 20 (02) : 57 - 65
  • [33] Diagnostic value of ultrasonographic combining biochemical markers for Down syndrome screening in first trimester: a meta-analysis
    Liu, Yang
    Ye, Xingguang
    Zhang, Na.
    Zhang, Baohuan
    Guo, Congcong
    Huang, Weihuang
    Jing, Lipeng
    Wang, Man
    Yang, Guang
    Wei, Xiangcai
    Jing, Chunxia
    PRENATAL DIAGNOSIS, 2015, 35 (09) : 879 - 887
  • [34] Comparison of First Trimester Screening for Down's Syndrome Using Free Beta-Human Chorionic Gonadotropin and Pregnancy-Associated Plasma Protein-A Levels between Spontaneous and IVF Pregnancies at 12 Weeks of Gestation
    Taheripanah, Robabeh
    Talayeh, Maryam
    Zamaniyan, Marzieh
    Khosravi, Donya
    Taheripanah, Anahita
    INTERNATIONAL JOURNAL OF FERTILITY & STERILITY, 2019, 13 (02) : 93 - 96
  • [35] First-trimester screening for Down syndrome using nuchal translucency measurement with free β-hCG and PAPP-A between 10 and 13 weeks of pregnancy -: the combined test
    De Biasio, P
    Siccardi, M
    Volpe, G
    Famularo, L
    Santi, F
    Canini, S
    PRENATAL DIAGNOSIS, 1999, 19 (04) : 360 - 363
  • [36] Are second-trimester minor sonographic markers for Down syndrome useful in patients who have undergone first-trimester combined screening?
    Sood, Monica
    Rochelson, Burton
    Krantz, David
    Ravens, Rachel
    Tam, Hima Tam
    Vohra, Nidhi
    Lewis, Dawnette
    Ray, Bidisha
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2010, 203 (04) : 408.e1 - 408.e4
  • [37] SERUM PAPP-A AND FREE BETA-HCG ARE FIRST-TRIMESTER SCREENING MARKERS FOR DOWN-SYNDROME
    BRAMBATI, B
    TULUI, L
    BONACCHI, I
    SHRIMANKER, K
    SUZUKI, Y
    GRUDZINSKAS, JG
    PRENATAL DIAGNOSIS, 1994, 14 (11) : 1043 - 1047
  • [38] Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome
    Spencer, K
    PRENATAL DIAGNOSIS, 2000, 20 (08) : 652 - 656
  • [39] Pregnancies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndrome
    Amor, D. J.
    Xu, J. X.
    Halliday, J. L.
    Francis, I.
    Healy, D. L.
    Breheny, S.
    Baker, H. W. G.
    Jaques, A. M.
    HUMAN REPRODUCTION, 2009, 24 (06) : 1330 - 1338
  • [40] Age-independent first trimester screening for Down syndrome: analysis of three modified software programs with 6,508 pregnancies
    Hoermansdoerfer, C.
    Golatta, M.
    Scharf, A.
    Hillemanns, P.
    Schmidt, P.
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2011, 283 (04) : 749 - 754